Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price8.96 USD
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown10.99-18.5% to today ✓Accumulation gives way to Markdown after an 18% slide in 3 weeks
2026-09-09Read Accumulation13.42-33.3% to today Markdown gives way to Accumulation first Accumulation read since July
2026-08-08Read Markdown13.42-33.3% to today ✓Accumulation gives way to Markdown after a 21% rise in 5 weeks
2026-07-02Read Accumulation11.13-19.5% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Polyrizon Ltd holds its Markdown at $8.96. Consolidating, no directional conviction, held for 156 days.
As held on the ledger · 2026-10-26
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 156 days
Price at the screen
$8.96
Valuation
N/A trailing · N/A forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
52.05%
Below 33%
Interest-bearing cash and securities are 52.1% of assets, above the one-third limit.
Fail
Receivables
6.09%
Below 49%
Money owed to the company is 6.1% of assets, under the 49% limit.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Polyrizon's business is fine, but its cash and interest-bearing securities are about 52% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PLRZ's ethical verdict changes
Today PLRZ does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Israel and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PLRZ trades on NASDAQ (the company is based in Israel). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-21Markdown$10.41-5.3%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 5.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is momentum reading neutral. Over the past year the shares are up 130%. Our forward projection puts the odds of a 10% gain over the next month near 15%.
2026-10-02Markdown · changed$10.99-18.1%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 18.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 130%. Our forward projection puts the odds of a 10% gain over the next month near 15%.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 130%. Our forward projection puts the odds of a 10% gain over the next month near 15%.
2026-08-08Markdown · changed$13.42+20.6%Entry 4
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 20.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 130%. Our forward projection puts the odds of a 10% gain over the next month near 15%.
2026-07-18Accumulation$11.13+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 21% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 130%. Our forward projection puts the odds of a 10% gain over the next month near 15%.
2026-07-03Accumulation$11.13+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$11.13Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.